Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 9/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28451145 | 0.80 | ALOX5AP (0.50) | PROKR1HPGDSALOX5APFEN1JAK2 | |
| SCHEMBL27211270 | 0.78 | HPGDS (0.48) | PROKR1PIK3CAHPGDSALOX5APFEN1 | |
| SCHEMBL30473720 | 0.78 | HPGDS (0.48) | PROKR1PIK3CAHPGDSALOX5APFEN1 | |
| SCHEMBL25346096 | 0.78 | HPGDS (0.48) | PROKR1PIK3CAHPGDSALOX5APFEN1 | |
| SCHEMBL25343585 | 0.78 | PDE4B (0.52) | PROKR1PIK3CAHPGDSALOX5APFEN1 | |
| SCHEMBL25345087 | 0.78 | PDE4B (0.52) | PROKR1PIK3CAHPGDSALOX5APFEN1 | |
| SCHEMBL30473677 | 0.78 | PDE4B (0.52) | PROKR1PIK3CAHPGDSALOX5APFEN1 | |
| SCHEMBL31654207 | 0.77 | PIK3CA (0.44) | PIK3CAALOX5APFEN1JAK2GPR119 | |
| SCHEMBL25888714 | 0.77 | PIK3CA (0.44) | PIK3CAALOX5APFEN1JAK2GPR119 | |
| SCHEMBL24662171 | 0.77 | PRMT5 (0.47) | PROKR1PIK3CAHPGDSALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2022073904-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | PROKR1 376/4885PIK3CA 4494/4885HPGDS 208/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | PROKR1 376/4885PIK3CA 4494/4885HPGDS 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.